Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666380 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00666380: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT00666380 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666380, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.
Primary Outcome
Occurrence and intensity of solicited symptoms on day of vaccination and Days 1-7 after each vaccination
Interventions
- BIOLOGICAL Plasmodium falciparum Malaria Protein 010 (FMP010)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00666380 record still lists
NCT00666380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Plasmodium falciparum Malaria Protein 010 (FMP010) is the first listed.
NCT00666380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666380 about?
NCT00666380 is a clinical study titled "A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya". The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.
What is the current status of trial NCT00666380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-04. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00666380?
The interventions under investigation include: Plasmodium falciparum Malaria Protein 010 (FMP010) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00666380?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666380's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia